ArticleEndocrine2017
Frequency, pattern, and outcome of recurrences after gamma knife radiosurgery for pituitary adenomas.
Article in Endocrine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Recurrent acromegaly: a systematic review on therapeutic approaches.BMC endocrine disorders · 2024Pooled it
- Radiation therapy in functioning and no functioning pituitary neuroendocrine tumor: systematic review of the recent literature after 2011.Frontiers in endocrinology · 2024Pooled it
- Stereotactic radiosurgery for non-functioning pituitary adenomas: meta-analysis and International Stereotactic Radiosurgery Society practice opinion.Neuro-oncology · 2020Pooled it
- Pooled it
- Pituitary Society Delphi consensus on the role of radiotherapy for pituitary adenomas.Pituitary · 2026Review
- Repeat gamma knife radiosurgery for recurrent pituitary adenomas.Journal of endocrinological investigation · 2025Article
- Stereotactic radiosurgery and fractionated radiation therapy in the management of pituitary tumors.Neuro-oncology advances · 2025Article
- Long-Term Outcomes After CyberKnife Radiosurgery for Nonfunctioning Pituitary Adenomas.Neurosurgery · 2025Article
- Long-term tumor control following repeat gamma-knife radiosurgery of growing pituitary adenomas: a population-based cohort study.Acta neurochirurgica · 2024Article
- Long-term tumor control following gamma-knife radiosurgery of recurrent or residual pituitary adenomas: a population-based cohort study.Acta neurochirurgica · 2024Observational
- Gamma knife radiosurgery is effective in patients with thyrotropin-secreting pituitary adenomas.Journal of endocrinological investigation · 2024Article
- Stereotactic radiosurgery for nonfunctioning pituitary tumor: A multicenter study of new pituitary hormone deficiency.Neuro-oncology · 2024Article
- Contemporary radiotherapy and radiosurgery techniques for refractory pituitary adenomas.Pituitary · 2023Article
- Radiation Therapy for Recurrent or Residual Pituitary Macroadenoma Invading Extrasellar Structures.Yonsei medical journal · 2022Article
- Review
- Gamma knife radiosurgery in patients with Nelson's syndrome.Journal of endocrinological investigation · 2021Observational
- Characteristic of Tumor Regrowth After Gamma Knife Radiosurgery and Outcomes of Repeat Gamma Knife Radiosurgery in Nonfunctioning Pituitary Adenomas.Frontiers in oncology · 2021Article
- Pituitary adenomas in elderly patients: clinical and surgical outcome analysis in a large series.Endocrine · 2019Article
- Safety and efficacy of multisession gamma knife radiosurgery for residual or recurrent pituitary adenomas.Endocrine · 2019Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gamma Knife radiosurgery is often used in pituitary adenomas. Aim of our study is to describe the characteristics and long-term outcome of patients with adenoma recurrence after Gamma Knife radiosurgery. We conducted a retrospective analysis of patients with pituitary adenoma treated by Gamma Knife radiosurgery between 1994 and 2014. Tumor recurrence was labeled as "in field" when the tumor growth occurred adjacent or within the prescribed isodose, whereas it was classified as "out of field" when the tumor growth occurred outside the prescribed isodose. Five hundred forty-three patients were included, 272 (50.1 %) had a nonfunctioning pituitary adenoma (NFPA) and 271 (49.9 %) patients had a hormone secreting-pituitary adenoma. The median follow-up after GKRS was 78 months (IQR, 36-125 months). Thirty-nine patients (7.2 %) had recurrence of disease and it was more frequent in patients with NFPA than in patients with hormone secreting adenomas (9.6 % vs. 4.8 %). The 10-yr progression-free survival in patients with NFPA was 78.7 % (95 % CI 69.5 - 87.9 %), as compared with 93.3 % (95 % CI 89.3 - 97.3 %; p < 0.01) in hormone secreting adenomas. Tumor recurrence was "in field" in 17 cases (43.6 %) and "out of field" in 22 cases (56.4 %). Seven of the 39 patients with recurrence died despite further treatments. Six of these patients had an "in field" recurrence. Recurrence of a pituitary adenoma after GKRS may occur several years after initial treatment. Distinction between "in field" and "out of field" tumor recurrence probably reflects two different pathophysiological mechanisms and may have prognostic importance.
Indexed as
Identifiers
27688011What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.